Sandoz publishes results of Ph I/III trials re biosimilar denosumab

Sep 19, 2022

Sandoz announced the results of its Ph I/III trials of its biosimilar denosumab.  Sandoz reported that the results confirm that the biosimilar matches the pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity of the reference product.

Print Page Mail Article